CD8A and neoplasm: The utilization of immune checkpoint inhibitors (ICIs) presents a hopeful strategy for managing advanced lung cancer due to their ability to enhance the CD8+ T cell-mediated response, which includes direct cytotoxic activity against tumor cells (1).